SEARCH:   Advanced

Blood, 15 February 2004, Vol. 103, No. 4, pp. 1472-1474. Prepublished online as a Blood First Edition Paper on October 16, 2003; DOI 10.1182/blood-2003-07-2548. This Article Full Text (PDF) All Versions of this Article: 2003-07-2548v1 103/4/1472    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Farag, S. S Articles by Byrd, J. C Search for Related Content PubMed PubMed Citation Articles by Farag, S. S Articles by Byrd, J. C Social Bookmarking                   What's this? Submitted July 29, 2003 Accepted October 7, 2003 FcRIIIa and FcRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia Sherif S Farag, Ian W Flinn, Rama Modali, Teresa A Lehman, Donn Young, and John C Byrd* Department of Medicine, The Ohio State University, Columbus, OH, USA Department of Oncology, Johns Hopkins University, Baltimore, MD, USA BioServe Biotechnologies Ltd, Laurel, MD, USA * Corresponding author; email: byrd-3{at}medctr.osu.edu. In follicular lymphoma (FL), genomic polymorphisms corresponding to phenotypic expression of valine (V) or phenylalanine (F) at amino acid 158 of FcRIIIa alter the binding affinity of IgG1 to the receptor, and have been associated with varied response to rituximab. We examined FcRIIIa polymorphisms of 30 CLL patients with the phenotypes V/V (n=6), V/F (n=12), and F/F (n=12) treated with thrice-weekly rituximab (375 mg/m2) for four weeks to correlate polymorphism type with infusion toxicity and response to therapy. Infusion toxicity (grade 3 or hypoxia/hypotension requiring transient cessation of therapy) was observed equally among the groups (V/V, 50%; V/F, 33; F/F, 41.6%; P=0.78). The response to rituximab was also similar among the different polymorphism phenotypes (V/V, 33%; V/F, 41.6%; F/F, 50%). These data suggest that FcRIIIa polymorphisms are not predictive of response in CLL, and that unlike the case with FL, mechanisms of tumor clearance other than antibody-dependent cellular cytotoxicity may be more important. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. I. Vega, S. Huerta-Yepez, M. Martinez-Paniagua, B. Martinez-Miguel, R. Hernandez-Pando, C. R. Gonzalez-Bonilla, P. Chinn, N. Hanna, K. Hariharan, A. R. Jazirehi, et al. Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions Clin. Cancer Res., November 1, 2009; 15(21): 6582 - 6594. [Abstract] [Full Text] [PDF] M. Leidi, E. Gotti, L. Bologna, E. Miranda, M. Rimoldi, A. Sica, M. Roncalli, G. A. Palumbo, M. Introna, and J. Golay M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro J. Immunol., April 1, 2009; 182(7): 4415 - 4422. [Abstract] [Full Text] [PDF] F. Bibeau, E. Lopez-Crapez, F. Di Fiore, S. Thezenas, M. Ychou, F. Blanchard, A. Lamy, F. Penault-Llorca, T. Frebourg, P. Michel, et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan J. Clin. Oncol., March 1, 2009; 27(7): 1122 - 1129. [Abstract] [Full Text] [PDF] R. Lapalombella, B. Yu, G. Triantafillou, Q. Liu, J. P. Butchar, G. Lozanski, A. Ramanunni, L. L. Smith, W. Blum, L. Andritsos, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells Blood, December 15, 2008; 112(13): 5180 - 5189. [Abstract] [Full Text] [PDF] B. D. Cheson and J. P. Leonard Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma N. Engl. J. Med., August 7, 2008; 359(6): 613 - 626. [Full Text] [PDF] N. M. Pennell, T. Bhanji, L. Zhang, A. Seth, C. A. Sawka, and N. L. Berinstein Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma Haematologica, August 1, 2008; 93(8): 1265 - 1267. [Full Text] [PDF] C. Meyer zum Buschenfelde, Y. Feuerstacke, K. S. Gotze, K. Scholze, and C. Peschel GM1 Expression of Non-Hodgkin's Lymphoma Determines Susceptibility to Rituximab Treatment Cancer Res., July 1, 2008; 68(13): 5414 - 5422. [Abstract] [Full Text] [PDF] S. Varchetta, N. Gibelli, B. Oliviero, E. Nardini, R. Gennari, G. Gatti, L. S. Silva, L. Villani, E. Tagliabue, S. Menard, et al. Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2 Cancer Res., December 15, 2007; 67(24): 11991 - 11999. [Abstract] [Full Text] [PDF] E. Oflazoglu, I. J. Stone, K. A. Gordon, I. S. Grewal, N. van Rooijen, C.-L. Law, and H.-P. Gerber Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30 Blood, December 15, 2007; 110(13): 4370 - 4372. [Abstract] [Full Text] [PDF] B. Z. Alizadeh, G. Valdigem, M. J.H. Coenen, A. Zhernakova, B. Franke, A. Monsuur, P. L.C.M. van Riel, P. Barrera, T. R.D.J. Radstake, B. O. Roep, et al. Association analysis of functional variants of the FcgRIIa and FcgRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis Hum. Mol. Genet., November 1, 2007; 16(21): 2552 - 2559. [Abstract] [Full Text] [PDF] W. Zhang, M. Gordon, A. M. Schultheis, D. Y. Yang, F. Nagashima, M. Azuma, H.-M. Chang, E. Borucka, G. Lurje, A. E. Sherrod, et al. FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab J. Clin. Oncol., August 20, 2007; 25(24): 3712 - 3718. [Abstract] [Full Text] [PDF] E. Carlotti, G. A. Palumbo, E. Oldani, D. Tibullo, S. Salmoiraghi, A. Rossi, J. Golay, A. Pulsoni, R. Foa, and A. Rambaldi Fc{gamma}RIIIA and Fc{gamma}RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab Haematologica, August 1, 2007; 92(8): 1127 - 1130. [Abstract] [Full Text] [PDF] Z. Mitrovic, I. Aurer, I. Radman, R. Ajdukovic, J. Sertic, and B. Labar FC{gamma}RIIIA and FC{gamma}RIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma Haematologica, July 1, 2007; 92(7): 998 - 999. [Abstract] [Full Text] [PDF] H. Horner, C. Frank, C. Dechant, R. Repp, M. Glennie, M. Herrmann, and B. Stockmeyer Intimate Cell Conjugate Formation and Exchange of Membrane Lipids Precede Apoptosis Induction in Target Cells during Antibody-Dependent, Granulocyte-Mediated Cytotoxicity J. Immunol., July 1, 2007; 179(1): 337 - 345. [Abstract] [Full Text] [PDF] J. G. Berdeja, A. Hess, D. M. Lucas, P. O'Donnell, R. F. Ambinder, L. F. Diehl, D. Carter-Brookins, S. Newton, and I. W. Flinn Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab Clin. Cancer Res., April 15, 2007; 13(8): 2392 - 2399. [Abstract] [Full Text] [PDF] C. Bello and E. M. Sotomayor Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and Beyond Hematology, January 1, 2007; 2007(1): 233 - 242. [Abstract] [Full Text] [PDF] J. A. Bowles, S.-Y. Wang, B. K. Link, B. Allan, G. Beuerlein, M.-A. Campbell, D. Marquis, B. Ondek, J. E. Wooldridge, B. J. Smith, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab Blood, October 15, 2006; 108(8): 2648 - 2654. [Abstract] [Full Text] [PDF] M. Alfonso-Perez, S. Lopez-Giral, N. E. Quintana, J. Loscertales, P. Martin-Jimenez, and C. Munoz Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia J. Leukoc. Biol., June 1, 2006; 79(6): 1157 - 1165. [Abstract] [Full Text] [PDF] Y. Hamaguchi, Y. Xiu, K. Komura, F. Nimmerjahn, and T. F. Tedder Antibody isotype-specific engagement of Fc{gamma} receptors regulates B lymphocyte depletion during CD20 immunotherapy J. Exp. Med., March 20, 2006; 203(3): 743 - 753. [Abstract] [Full Text] [PDF] P. V. Beum, A. D. Kennedy, M. E. Williams, M. A. Lindorfer, and R. P. Taylor The Shaving Reaction: Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Cells by THP-1 Monocytes J. Immunol., February 15, 2006; 176(4): 2600 - 2609. [Abstract] [Full Text] [PDF] E A Clark and J A Ledbetter How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv77 - iv80. [Abstract] [Full Text] [PDF] M. Ghielmini, K. Rufibach, G. Salles, L. Leoncini-Franscini, C. Leger-Falandry, S. Cogliatti, M. Fey, G. Martinelli, R. Stahel, A. Lohri, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK) Ann. Onc., October 1, 2005; 16(10): 1675 - 1682. [Abstract] [Full Text] [PDF] W. G. Wierda, T. J. Kipps, and M. J. Keating Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia J. Clin. Oncol., September 10, 2005; 23(26): 6325 - 6332. [Abstract] [Full Text] [PDF] D. Ternant, M. Ohresser, C. Thomas, G. Cartron, H. Watier, G. Paintaud, A. Hubsch, M. Spycher, J. Bichler, and S. Miescher Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies Blood, August 15, 2005; 106(4): 1503 - 1505. [Full Text] [PDF] Y. Hamaguchi, J. Uchida, D. W. Cain, G. M. Venturi, J. C. Poe, K. M. Haas, and T. F. Tedder The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice J. Immunol., April 1, 2005; 174(7): 4389 - 4399. [Abstract] [Full Text] [PDF] P. Carter and C. F. McDonagh Designer Antibody-Based Therapeutics for Oncology Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 147 - 154. [Full Text] [PDF] Q. Gong, Q. Ou, S. Ye, W. P. Lee, J. Cornelius, L. Diehl, W. Y. Lin, Z. Hu, Y. Lu, Y. Chen, et al. Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy J. Immunol., January 15, 2005; 174(2): 817 - 826. [Abstract] [Full Text] [PDF] T. S. Lin, I. W. Flinn, R. Modali, T. A. Lehman, J. Webb, S. Waymer, M. E. Moran, M. S. Lucas, S. S. Farag, and J. C. Byrd FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia Blood, January 1, 2005; 105(1): 289 - 291. [Abstract] [Full Text] [PDF] T. Ishida, S. Iida, Y. Akatsuka, T. Ishii, M. Miyazaki, H. Komatsu, H. Inagaki, N. Okada, T. Fujita, K. Shitara, et al. The CC Chemokine Receptor 4 as a Novel Specific Molecular Target for Immunotherapy in Adult T-Cell Leukemia/Lymphoma Clin. Cancer Res., November 15, 2004; 10(22): 7529 - 7539. [Abstract] [Full Text] [PDF] G. Cartron, H. Watier, J. Golay, and P. Solal-Celigny From the bench to the bedside: ways to improve rituximab efficacy Blood, November 1, 2004; 104(9): 2635 - 2642. [Abstract] [Full Text] [PDF] A. J. Olszewski and M. L. Grossbard Empowering Targeted Therapy: Lessons from Rituximab Sci. Signal., July 13, 2004; 2004(241): pe30 - pe30. [Abstract] [Full Text] [PDF] J. Uchida, Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor-dependent Mechanisms during Anti-CD20 Antibody Immunotherapy J. Exp. Med., June 21, 2004; 199(12): 1659 - 1669. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020